Theodore Karrison to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Theodore Karrison has written about Antimetabolites, Antineoplastic.
Connection Strength
0.066
-
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
Score: 0.054
-
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol. 2003 Oct; 170(4 Pt 1):1141-5.
Score: 0.012